📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-20 11:48
510 analysed today
510
Today
133,399
All-time analysed
40,108
Positive
6,279
Negative
79,197
Neutral
7,747
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
25 announcements match the current filters (relevance ≥ 5).
Marksans Pharma Q1 FY27 Concall: PAT Jumps 174% YoY to ₹159 Cr; Targets ₹4,000 Cr Revenue in 2 Yrs
Marksans Pharma reported robust Q1 FY27 operational results with revenue growing 35.6% YoY to ₹840.8 crore, driven by a 74.7% surge in the UK and Europe segment to ₹356 crore (aided by the QliniQ acquisition). EBITDA increased 112.8% YoY to ₹213 crore with margins expanding 919 bps to 25.3%, while PAT climbed 173.9% YoY to ₹159.4 crore. The company generated free cash flow of ₹152 crore, taking its cash balance above ₹1,000 crore to ₹1,058 crore. Management reiterated its growth guidance of 15-20% for FY27 and maintained its strategic target to reach ₹4,000 crore in revenue within two years.
Confidence: HIGH
What changedSubmission of the formal transcript of the Q1 FY27 investor/analyst earnings call held on August 13, 2026.
Why it mattersProvides management commentary on European expansion, margin drivers (operating leverage and low-cost inventory benefit), and strategic capital allocation for inorganic opportunities using its ₹1,000+ crore cash balance.
Q1 FY27 Operating Revenue: ₹840.8 crQ1 FY27 EBITDA: ₹213.0 crQ1 FY27 PAT: ₹159.4 crCash & Net Cash Balance: ₹1,058 cr / ₹1,031 crQliniQ Q1 Revenue Contribution: ₹44 cr
📅 Short termPositive sentiment from record quarterly performance, strong cash conversion, and lower working capital cycle.
📈 Long termUnderpins the company's trajectory toward achieving ₹4,000 crore revenue within two years through European front-end acquisitions and US private label OTC expansion.
⚠ Risk flags
- Geopolitical risks and elevated freight/solvent raw material costs that could compress gross margins towards the 55-56% baseline.
- Potential integration risks with newly acquired European entities (QliniQ and ABCnow).
Key Highlights
Q1 FY27 revenue rose 35.6% YoY to ₹840.8 crore, with North America at ₹377 crore (+15.1% YoY) and UK & Europe at ₹356 crore (+74.7% YoY).
EBITDA more than doubled to ₹213 crore (+112.8% YoY) with EBITDA margin expanding by 919 bps to 25.3%.
Net profit surged 173.9% YoY to ₹159.4 crore, while PAT margin improved to 18.4% from 9.3% in Q1 FY26.
Free cash flow generation stood at ₹152 crore, boosting total cash and cash equivalents to ₹1,058 crore (net cash of ₹1,031 crore).
Working capital cycle reduced to 132 days from 159 days in Q1 FY26, driven by inventory normalization.
👀 What to Watch
Track the integration and performance of European acquisitions (QliniQ and ABCnow GmbH) along with sustainability of gross margins (management normalized target of 55-56% vs 59.1% in Q1).
174% PAT Growth: Marksans Pharma Reports Record Q1FY27 with ₹213 Cr EBITDA
Marksans Pharma delivered a record-breaking Q1FY27, with PAT surging 173.9% YoY to ₹159.4 cr and EBITDA rising 112.8% to ₹213 cr. Revenue grew 35.6% YoY to ₹840.8 cr, driven by a 74.7% jump in the UK & Europe segment, which hit an all-time high of ₹356 cr. EBITDA margins expanded significantly by 919 bps YoY to 25.3%, reflecting strong operating leverage and the integration of European acquisitions. The company's cash balance crossed the ₹1,000 cr milestone for the first time, reaching ₹1,058 cr.
Confidence: HIGH
What changedMarksans has achieved a new baseline of profitability with record margins and revenue, significantly exceeding its TTM OPM of 21.5%.
Why it mattersThe results validate the company's strategy of expanding its front-end presence in Europe (via QliniQ) and scaling its manufacturing capacity, leading to superior operating leverage and cash generation.
Q1FY27 Revenue: ₹840.8 crEBITDA Margin: 25.3%PAT Growth (YoY): 173.9%Cash Balance: ₹1,058 crRevenue vs TTM Revenue: ~31.7%
📅 Short termThe stock is likely to react positively to the substantial earnings beat and the milestone of crossing ₹1,000 cr in cash.
📈 Long termThe structural shift toward higher-margin European markets and a debt-free, cash-rich balance sheet supports the company's long-term goal of reaching ₹3,000 cr in revenue.
⚠ Risk flags
- Pricing pressure in the UK market
- Geopolitical delays impacting RoW shipments
- Integration risks of newly acquired European entities
Key Highlights
PAT increased 173.9% YoY to ₹159.4 cr, with net margins improving to 18.4%.
EBITDA margin expanded to 25.3%, up from 16.1% in the same quarter last year.
UK & Europe revenue grew 74.7% YoY to ₹356 cr, now representing 42.3% of total revenue.
Cash and cash equivalents reached ₹1,058 cr as of June 30, 2026, despite recent acquisitions.
Working capital cycle improved to 132 days from 159 days in Q1FY26.
👀 What to Watch
Investors should monitor the sustainability of the 25%+ EBITDA margins in upcoming quarters and watch for the deployment of the ₹1,058 cr cash reserve toward the company's stated inorganic growth strategy.
Marksans Pharma Q1 FY27 PAT Jumps 174% to ₹159 Cr; EBITDA Margins Hit Record 25.3%
Marksans Pharma delivered a robust Q1 FY27 with revenue growing 35.6% YoY to ₹841 cr, primarily driven by a 74.7% surge in the UK & Europe segment. Profitability outperformed revenue growth significantly, with PAT rising 173.9% to ₹159 cr and EBITDA margins expanding by 919 bps to 25.3% due to operating leverage and a better product mix. The company achieved a milestone cash balance of ₹1,058 cr, representing ~8.3% of its market cap, providing substantial liquidity for further inorganic growth. The acquisition of QliniQ contributed ₹44 cr to the top line, marking a successful start to its European front-end expansion.
Confidence: HIGH
What changedMarksans has successfully transitioned to a front-end model in parts of Europe (via QliniQ) and achieved significant operating leverage from its Unit 2 facility.
Why it mattersThe sharp margin expansion and record cash levels indicate the business is generating high-quality free cash flow, which is being used to fund a shift from a wholesale-led model to a higher-margin direct-to-market model in Europe and North America.
Q1 FY27 Revenue: ₹841 crEBITDA Margin: 25.3%PAT Growth (YoY): 173.9%Cash Balance vs Market Cap: ~8.3%UK & Europe Revenue Growth: 74.7%
📅 Short termThe stock is likely to react positively to the significant earnings beat and margin expansion, which far exceeds the TTM OPM of 21.5%.
📈 Long termThe company is structurally moving towards its ₹3,000 cr revenue target with a strong balance sheet and a growing front-end presence in regulated markets like Germany and Canada.
⚠ Risk flags
- Seasonal softness in US and ANZ markets (QoQ revenue dip)
- Integration risks of multiple new European entities
- Potential normalization of margins if freight or raw material costs rise
Key Highlights
Revenue increased 35.6% YoY to ₹841 cr, with UK & Europe contributing ₹356 cr (42.3% of total).
EBITDA grew 112.8% YoY to ₹213 cr, with margins expanding from 16.1% to 25.3%.
Net cash balance crossed the ₹1,000 cr mark for the first time, ending at ₹1,058 cr.
The newly acquired QliniQ B.V. (Netherlands) contributed ₹44 cr to revenue in its first consolidated quarter.
Working capital cycle improved to 132 days from 159 days in the previous year's quarter.
👀 What to Watch
Monitor the integration of ABCnow GmbH in Germany and the commencement of commercial revenue from the new Canada entity in upcoming quarters. Investors should also track if the 25%+ EBITDA margin is sustainable as the company ramps up R&D and expansion costs.
174% PAT growth: Marksans Pharma Q1 profit hits ₹159.4 Cr; expands in Europe via acquisitions
Marksans Pharma reported a strong Q1 FY27 with consolidated Profit After Tax (PAT) surging 173.9% YoY to ₹159.41 Cr. The company significantly expanded its European footprint by acquiring 100% of QliniQ B.V. (Netherlands) for EUR 7.50 Million and entering a definitive agreement for ABCnow GmbH (Germany) for EUR 1.10 Million. Consolidated EPS improved to ₹3.47 from ₹1.28 in the previous year's quarter. While standalone revenue growth was flat at 0.4% YoY, the consolidated performance reflects strong contributions from subsidiaries and new acquisitions.
Confidence: HIGH
What changedMarksans Pharma reported a massive jump in consolidated profitability and completed two strategic acquisitions to establish a direct frontend presence in the Netherlands and Germany.
Why it mattersThe acquisitions shift the business model from distributor-led to direct frontend sales in key European markets, which is critical for the company's goal to reach ₹3,000 Cr in revenue and become a top 5 private label OTC player.
Consolidated PAT (Q1): ₹159.41 CrYoY PAT Growth: 173.9%Total Acquisition Value: EUR 8.60 MillionConsolidated EPS: ₹3.47Standalone Revenue: ₹321.19 CrAcquisition vs TTM Revenue: ~3.1%
📅 Short termThe stock is likely to see positive momentum driven by the triple-digit profit growth and the strategic expansion into the European market.
📈 Long termStructural growth is supported by the transition to a frontend-led model in Europe and the doubling of low-cost manufacturing capacity in India.
⚠ Risk flags
- Integration risks of European acquisitions
- Pricing pressure in the UK market
- Elevated freight costs due to Red Sea crisis
Key Highlights
Consolidated PAT increased 173.9% YoY to ₹159.41 Cr from ₹58.20 Cr in Q1 FY26
Acquired 100% of QliniQ B.V. (Netherlands) for EUR 7.50 Million (approx. ₹70 Cr) effective April 1, 2026
Acquired ABCnow GmbH (Germany) for EUR 1.10 Million (approx. ₹10 Cr) to gain frontend sales capabilities
Consolidated EPS rose to ₹3.47 compared to ₹1.28 in the year-ago period
Other income included a net foreign exchange gain of ₹12.00 Cr at the consolidated level
👀 What to Watch
Monitor the integration of the new European subsidiaries and their impact on consolidated margins. Watch for the ramp-up of the Teva facility (Unit 2) and progress on the planned doubling of India-based manufacturing capacity to 16 billion units.
Marksans Pharma Completes 100% Acquisition of Germany-based ABCnow GmbH
Marksans Pharma has successfully completed the acquisition of 100% share capital of ABCnow GmbH, based in Germany. This move aligns with the company's stated strategic goal to reach Rs 3,000 Cr in revenue by expanding its footprint in the European market. While the acquisition cost was not disclosed in this filing, the company had previously raised Rs 372.40 Cr via warrants to fund such growth initiatives. This acquisition follows an initial intimation made on July 8, 2026, and marks a concrete step in the company's geographic diversification strategy.
Confidence: MEDIUM
What changedMarksans Pharma has finalized the takeover of ABCnow GmbH, transitioning it from a target to a 100% owned subsidiary.
Why it mattersThe acquisition provides a direct entry point into the German pharmaceutical market, reducing dependence on the US and UK markets where the company has faced pricing pressures and margin compression (258 bps decline in Q2 FY26).
Acquisition Stake: 100%TTM Revenue: Rs 2650 CrRevenue Target: Rs 3000 CrAcquisition Cost: not disclosedCompletion Date: 20 July 2026
📅 Short termThe completion of the acquisition is likely to be viewed positively by the market as it demonstrates execution of the company's stated expansion strategy.
📈 Long termThis is a structural move to establish a presence in Germany, which, if scaled successfully alongside the planned doubling of Indian capacity, could significantly contribute to the Rs 3,000 Cr revenue goal.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Integration risk of a foreign entity
- Lack of disclosure on acquisition valuation
- Regulatory hurdles in the German OTC market
Key Highlights
Acquisition of 100% share capital of ABCnow GmbH completed on July 20, 2026
Strategic entry into the German market to support the Rs 3,000 Cr revenue target
Follows a prior intimation regarding the deal dated July 8, 2026
Company aims to double India manufacturing capacity from 8 billion to 16 billion units p.a.
👀 What to Watch
Investors should monitor upcoming quarterly results for the financial contribution of the German entity and management's guidance on the integration timeline. Watch for updates on regulatory filings in Germany which are critical for organic growth in that region.
Marksans Pharma to Acquire 100% of German Firm ABCnow GmbH for € 892,384
Marksans Pharma has entered into a definitive agreement to acquire 100% of ABCnow GmbH, a German pharmaceutical distributor, for a cash consideration of € 892,384 (approx. ₹8.1 Cr). The acquisition provides Marksans with a direct front-end sales and marketing infrastructure in Germany, facilitating the distribution of products manufactured in its India, UK, and USA facilities. While the target's 2025 revenue of € 227,233 is small (less than 0.5% of Marksans' TTM revenue of ₹2,650 Cr), it fulfills a stated strategic goal to expand into the German market. The transaction is expected to close by July 31, 2026.
Confidence: HIGH
What changedMarksans has transitioned from an organic entry plan in Germany to an inorganic acquisition of a local distribution front-end.
Why it mattersThis provides the company with direct market access in Germany, a key regulated market, supporting its long-term goal of reaching ₹3,000 Cr in revenue and reducing reliance on third-party distributors.
Cost of acquisition: € 892,384Target Revenue (2025): € 227,233.69Acquisition vs TTM Revenue: ~0.31%Expected Completion Date: 31 July 2026
📅 Short termThe small financial scale of the deal suggests limited immediate impact on the stock price, though it confirms management's execution of its stated expansion strategy.
📈 Long termStructurally significant as it establishes a base in Germany; the long-term value depends on Marksans' ability to scale its OTC and prescription products through this new European hub.
⚠ Risk flags
- Target revenue showed a significant decline from 2024 to 2025
- Integration risk of a foreign distribution entity
Key Highlights
Acquisition of 100% share capital for a total cash consideration of € 892,384
Target company ABCnow GmbH reported a 2025 turnover of € 227,233.69, down from € 510,215.60 in 2024
The acquisition is expected to be completed by July 31, 2026
ABCnow is a pharmaceutical wholesale and distribution company incorporated in 2023, based in Flensburg, Germany
Strategic move to establish a direct front-end in the European Union for forward integration
👀 What to Watch
Watch for the successful integration of the German front-end and the timeline for launching Marksans' existing product portfolio through this new distribution channel.
₹ 0.90 Dividend: Marksans Pharma Sets August 20 as Record Date for FY26 Final Dividend
Marksans Pharma has finalized the timeline for its FY26 final dividend of ₹ 0.90 per share (90% of face value). The record date to determine shareholder eligibility is fixed for August 20, 2026, with the Annual General Meeting (AGM) scheduled for August 27, 2026. If approved at the AGM, the dividend will be paid starting September 10, 2026. This follows the board's recommendation made on May 26, 2026.
Confidence: HIGH
What changedThe company has moved from a dividend recommendation to fixing the specific execution dates (Record Date and AGM) for the FY26 payout.
Why it mattersWhile the dividend yield is modest at approximately 0.33%, it confirms the company's commitment to regular shareholder distributions alongside its growth investments in capacity expansion.
Dividend per share: ₹ 0.90Record Date: August 20, 2026Dividend Yield: ~0.33%TTM EPS: ₹ 9.00AGM Date: August 27, 2026
📅 Short termThe stock may see minor price adjustments around the ex-dividend date in August, though the small yield suggests minimal volatility from this event.
📈 Long termLimited; this is a routine administrative filing for an annual dividend distribution.
Key Highlights
Final dividend of ₹ 0.90 per equity share of face value ₹ 1 each
Record date for dividend eligibility fixed as August 20, 2026
34th Annual General Meeting scheduled for August 27, 2026, at 11:00 AM
Dividend payment to commence on or after September 10, 2026
Dividend payout represents a 10% payout ratio against TTM EPS of ₹ 9.00
👀 What to Watch
Investors interested in the dividend must hold the shares before the ex-dividend date (typically one day prior to the August 20 record date). Monitor the upcoming AGM for management commentary on the ₹ 3,000 Cr revenue target.
₹0.90 Dividend: Marksans Pharma Sets Aug 20 as Record Date for FY26 Final Dividend
Marksans Pharma has scheduled its 34th Annual General Meeting (AGM) for August 27, 2026. The company has fixed August 20, 2026, as the record date to determine eligibility for a final dividend of ₹0.90 per share (90% of face value). Based on the TTM EPS of ₹9.00, this represents a dividend payout ratio of approximately 10%. The dividend, if approved, will be paid starting September 10, 2026.
Confidence: HIGH
What changedThe company has finalized the administrative timeline for its AGM and the record date for the FY26 final dividend payment.
Why it mattersThis is a routine corporate action that confirms the distribution of profits to shareholders and provides the schedule for the annual shareholder meeting.
Final Dividend: ₹0.90 per shareDividend Payout Ratio (TTM): 10%Record Date: August 20, 2026AGM Date: August 27, 2026Payment Date: September 10, 2026
📅 Short termThe stock price may adjust by the dividend amount on the ex-dividend date. No major price volatility is expected from this routine announcement.
📈 Long termLimited structural significance; however, consistent dividend payments reflect the company's stable cash flow position (Debt/Equity of 0.01).
Key Highlights
Final dividend recommended at ₹0.90 per equity share of face value ₹1 each
Record date for dividend eligibility fixed as Thursday, August 20, 2026
34th Annual General Meeting scheduled for Thursday, August 27, 2026, via VC/OAVM
Dividend payment to commence on or after September 10, 2026, subject to shareholder approval
Dividend payout represents approximately 10% of the TTM EPS of ₹9.00
👀 What to Watch
Investors interested in the dividend must hold the shares before the ex-dividend date (typically one day before the record date). Monitor the upcoming Annual Report for management commentary on the progress toward the ₹3,000 Cr revenue target.
₹0.90 Dividend: Marksans Pharma Sets August 20, 2026, as Record Date
Marksans Pharma has announced August 20, 2026, as the record date for its final dividend of ₹0.90 per equity share for FY26. This dividend represents a 90% payout on the face value of ₹1 and follows a strong financial year with TTM PAT of ₹410 Cr. The payout is subject to shareholder approval at the upcoming 34th Annual General Meeting (AGM) on August 27, 2026. If approved, the dividend will be paid starting September 10, 2026.
Confidence: HIGH
What changedThe company has finalized the administrative timeline (Record Date and AGM date) for its previously recommended FY26 final dividend.
Why it mattersIt confirms the cash return to shareholders from the company's earnings, though the yield is relatively low at 0.33% compared to the stock's recent 60.9% three-month price return.
Dividend per share: ₹0.90Record Date: 20-Aug-2026Dividend Yield: 0.33%TTM EPS: ₹9.00AGM Date: 27-Aug-2026
📅 Short termThe stock may see minor price adjustments around the ex-dividend date in August, but the small yield suggests minimal volatility from this specific event.
📈 Long termLimited structural significance; the long-term thesis remains tied to the doubling of India manufacturing capacity and US OTC market expansion.
Key Highlights
Final dividend recommended at ₹0.90 per equity share of face value ₹1 each.
Record date for determining dividend eligibility is fixed for August 20, 2026.
34th Annual General Meeting (AGM) scheduled for August 27, 2026, via video conferencing.
Dividend payment to be processed on or after September 10, 2026, post-AGM approval.
Dividend yield is approximately 0.33% based on the current market price of ₹269.0.
👀 What to Watch
Investors interested in the dividend must hold shares before the ex-dividend date (typically one working day prior to the August 20 record date). Monitor the AGM for management commentary on the progress toward the ₹3,000 Cr revenue target.
₹0.90 Final Dividend: Marksans Pharma Sets Aug 20 as Record Date for FY26
Marksans Pharma has finalized the timeline for its FY26 final dividend of ₹0.90 per share (90% of face value). The record date for eligibility is fixed as August 20, 2026, with the 34th AGM scheduled for August 27, 2026. Based on the TTM EPS of ₹9.00, this represents a conservative payout ratio of approximately 10%. The dividend yield at the current market price of ₹269 is approximately 0.33%.
Confidence: HIGH
What changedThe company has formalized the dates for its Annual General Meeting and the record date for the previously recommended final dividend for FY26.
Why it mattersThis is a routine corporate action that confirms the timeline for cash returns to shareholders. The low payout ratio indicates the company is likely retaining earnings to fund its stated expansion plans in the US and Germany.
Final Dividend: ₹0.90 per shareDividend Yield: ~0.33%Dividend Payout Ratio: ~10%Record Date: August 20, 2026AGM Date: August 27, 2026
📅 Short termThe stock is expected to remain neutral in the short term as the dividend yield is relatively low and the announcement is procedural.
📈 Long termLimited structural significance; the company's long-term value depends on its ability to scale its US OTC business and manage pricing pressures in the UK.
Key Highlights
Final dividend of ₹0.90 per equity share (90% of face value) recommended for FY26.
Record date for determining dividend eligibility is August 20, 2026.
34th Annual General Meeting (AGM) scheduled for August 27, 2026.
Dividend payment to be processed on or after September 10, 2026, subject to shareholder approval.
👀 What to Watch
Investors should monitor the upcoming Annual Report for updates on the company's strategy to double India manufacturing capacity and reach the ₹3,000 Cr revenue target.
Marksans Pharma FY26 Net Profit Jumps 60% to ₹3,007 Million; Re-submits Legible Results
Marksans Pharma re-submitted its audited financial results for FY26 in a machine-readable format following a request from the NSE. For the full year ended March 31, 2026, the company reported a significant 60% growth in Profit After Tax (PAT) to ₹3,006.98 million compared to ₹1,882.72 million in the previous year. Revenue from operations grew by 14.2% to ₹13,414.76 million. The company's EPS improved from ₹4.15 to ₹6.64, reflecting strong operational performance and margin expansion.
Key Highlights
Full-year FY26 Revenue from operations increased 14.2% YoY to ₹13,414.76 million.
Net Profit (PAT) for FY26 surged 59.7% to ₹3,006.98 million from ₹1,882.72 million in FY25.
Earnings Per Share (EPS) rose significantly to ₹6.64 for the full year, up from ₹4.15 in the previous fiscal.
Profit Before Tax (PBT) for the year stood at ₹3,915.43 million, a 61% increase over FY25.
Total Comprehensive Income for FY26 reached ₹3,017.39 million, compared to ₹1,879.71 million in FY25.
👀 What to Watch
The strong growth in both top-line and bottom-line figures indicates robust business momentum and improved profitability. Investors should focus on the fundamental growth trajectory rather than the minor administrative re-filing requested by the exchange.
Marksans Pharma Completes 100% Acquisition of Netherlands-based QliniQ B.V.
Marksans Pharma Limited has successfully finalized the acquisition of 100% share capital of QliniQ B.V., a company based in the Netherlands. This announcement follows the initial intimation provided on June 1, 2026, confirming the completion of the transaction. The acquisition is a strategic step to enhance the company's presence in the European pharmaceutical market. Investors should view this as a completion of a growth-oriented expansion move.
Key Highlights
Successfully completed the acquisition of 100% share capital of QliniQ B.V.
The target company, QliniQ B.V., is based in the Netherlands, expanding Marksans' European footprint.
The transaction was concluded on June 16, 2026, following the initial agreement on June 1, 2026.
The acquisition aligns with the company's strategy for international inorganic growth.
👀 What to Watch
Investors should monitor the integration process and look for the financial contribution of QliniQ B.V. in the upcoming quarterly earnings reports. The stock remains a 'Watch' for long-term growth driven by international expansion.
Marksans Pharma Credit Outlook Upgraded to Positive; Ratings Affirmed at IND AA-
India Ratings and Research (Fitch Group) has revised the outlook for Marksans Pharma's bank loan facilities from 'Stable' to 'Positive'. The agency affirmed the long-term rating at 'IND AA-' and the short-term rating at 'IND A1+' for facilities totaling ₹195.75 crore. This outlook revision indicates a potential for a future rating upgrade, reflecting the company's strengthening credit profile and financial stability.
Key Highlights
Outlook revised to Positive from Stable by India Ratings and Research.
Long-term rating affirmed at 'IND AA-' and short-term rating at 'IND A1+'.
The credit rating applies to bank loan facilities amounting to ₹195.75 crore.
Revision signals improving fundamental financial health and lower credit risk for the company.
👀 What to Watch
Investors should view this as a positive signal of the company's improving solvency and financial discipline. This upgrade could lead to lower borrowing costs for the company in the future.
Marksans Pharma FY26 Revenue Crosses ₹3,000 Cr; Q4 EBITDA Margin Hits 22.8%
Marksans Pharma achieved a significant milestone in FY26, crossing ₹3,000 crore in annual revenue with a 12.5% YoY growth. The company reported its highest-ever profitability, with Q4 EBITDA margins expanding to 22.8% driven by strong execution in North America and Australia. The balance sheet remains robust with ₹990 crore in cash and zero debt, supporting a final dividend recommendation of ₹0.90 per share. Management has reiterated a revenue target of ₹4,000 crore by FY28.
Key Highlights
Annual revenue reached ₹2,951 crore (approx. ₹3,000 Cr), led by 24% growth in the North American market.
Q4 FY26 EBITDA margin expanded by 491 bps YoY to 22.8%, reflecting strong operating leverage.
Australia and New Zealand markets saw a massive 61.3% YoY growth in Q4 following entry into branded prescription generics.
Maintains a debt-free status with cash and cash equivalents totaling ₹990 crore as of March 31, 2026.
Management warned of 20-30% raw material cost inflation in petroleum-related ingredients for Q1 FY27 due to geopolitical issues.
👀 What to Watch
Investors should focus on the company's successful scale-up of the Teva facility and its entry into new regulated markets like Germany and Canada. While near-term raw material inflation is a headwind, the strong cash position and margin trajectory support a positive long-term outlook.
Marksans Pharma to Acquire 100% of Netherlands-based QliniQ B.V. for €7.5 Million
Marksans Pharma has entered into a definitive agreement to acquire 100% of QliniQ B.V., a profitable Dutch pharmaceutical distributor, for a cash consideration of €7.5 million. QliniQ reported a revenue of €9.35 million and a net profit of €1.01 million for FY2025, showcasing a robust revenue CAGR of 41% since FY2023. This acquisition provides Marksans with direct front-end access to the Netherlands market, including established relationships with wholesalers, hospitals, and insurer-led tender channels. The deal is expected to close by June 15, 2026, and will be funded through cash reserves.
Key Highlights
Acquisition of 100% share capital of QliniQ B.V. for a total consideration of €7.5 million.
Target company reported FY2025 revenue of €9.35 million and net profit of €1.01 million with zero debt.
QliniQ has achieved a high-growth trajectory with a revenue CAGR of approximately 41% between FY2023 and FY2025.
Strategic expansion into the European Union through direct market access and EU GDP-compliant distribution infrastructure.
Marksans reported consolidated total income of ₹3,033 crore and PAT of ₹420 crore for the financial year ended March 31, 2026.
👀 What to Watch
Investors should view this as a positive strategic move that strengthens Marksans' forward-integration and European footprint at a reasonable valuation. Monitor the successful integration of QliniQ’s distribution network to see how it accelerates the commercialization of Marksans' existing product pipeline in the EU.
Marksans Pharma Hits Historic Triple: FY26 Revenue ₹3,033 Cr, PAT ₹420 Cr, Q4 PAT Up 64%
Marksans Pharma delivered record-breaking financial results for FY26, meeting its guidance with a total income of ₹3,033 crore and an all-time high PAT of ₹420 crore. The company showed exceptional momentum in Q4FY26, with PAT surging 64.3% YoY to ₹149 crore and EBITDA margins expanding significantly to 22.8%. Growth was fueled by 112 new SKU launches in the US and a strong recovery in the UK market. With a cash balance of ₹990 crore and the major capex cycle nearly complete, the company is well-positioned for sustainable future growth.
Key Highlights
FY26 Total Income reached ₹3,033 crore, up 12.8% YoY, while Q4FY26 income rose 23.1% to ₹891 crore.
Q4FY26 PAT jumped 64.3% YoY to ₹149 crore, with EBITDA margins improving by 491 bps to 22.8%.
US & North America revenue grew to ₹1,533 crore in FY26, representing 52% of the total revenue mix.
The company maintains a strong net cash position of ₹990 crore with ₹458 crore generated from operations in FY26.
Successfully launched 112 new SKUs in the US and entered new markets including Germany, Canada, and Ireland.
👀 What to Watch
Investors should take note of the significant margin expansion and the company's ability to deliver on its high-growth guidance. The strong cash position and completion of the capex cycle suggest potential for further market expansion or improved shareholder returns.
Marksans Pharma FY26 PAT Hits All-Time High of ₹420 Cr; Total Income Crosses ₹3,000 Cr Milestone
Marksans Pharma reported a milestone FY26 with total income reaching ₹3,033 crore, a 12.8% YoY increase, driven by strong growth in the US and Australia. The company achieved its highest-ever annual PAT of ₹420 crore and maintains a robust net cash position of ₹990 crore. Q4FY26 was particularly strong with a 64.3% YoY jump in PAT to ₹149 crore, supported by the launch of 11 new Rx brands in Australia and a recovery in the UK market. Management highlighted that the major capex cycle is nearly complete, positioning the company for sustainable long-term growth.
Key Highlights
Total Income for FY26 reached ₹3,033 crore, crossing the ₹3,000 crore milestone for the first time.
Q4FY26 PAT surged 64.3% YoY to ₹149 crore, with EBITDA margins expanding to 22.8%.
US market remains the largest contributor (52% of revenue) with 112 new SKUs launched in FY26.
Australia & NZ revenue grew 19.9% YoY, bolstered by the launch of the new Branded Prescription Division, Nova Pharma.
Strong balance sheet with a cash balance of ₹990 crore and a net cash positive status.
👀 What to Watch
Investors should monitor the scaling of the new Rx division in Australia and the margin benefits from the completed capex cycle. The company's strong cash position and growth in the US OTC market provide a solid foundation for long-term value.
Marksans Pharma Recommends Final Dividend of Rs. 0.90 per Share for FY 2025-26
Marksans Pharma's Board has recommended a final dividend of Rs. 0.90 per equity share for the financial year ended March 31, 2026. This represents a 90% payout on the face value of Re. 1 per share. The company also confirmed the approval of its audited financial results for both the quarter and the full year with an unmodified audit opinion from MSKA & Associates LLP. The dividend is subject to shareholder approval at the upcoming Annual General Meeting and will be processed within 30 days thereafter.
Key Highlights
Recommended a final dividend of Rs. 0.90 per equity share, representing a 90% payout on face value.
Audited financial results for Q4 and FY26 approved with an unmodified audit opinion.
Dividend to be credited or dispatched within 30 days from the date of the Annual General Meeting.
The Board meeting concluded on May 26, 2026, following the review of standalone and consolidated results.
👀 What to Watch
Investors should track the upcoming AGM date and record date to ensure eligibility for the dividend payout. The 90% dividend recommendation reflects management's confidence in the company's cash flow and financial health.
Marksans Pharma Reports FY26 Audited Results; Recommends ₹0.90 Final Dividend
Marksans Pharma Limited has approved its audited financial results for the quarter and fiscal year ended March 31, 2026. The Board has recommended a final dividend of ₹0.90 per equity share of ₹1 face value, representing a 90% payout. The statutory auditors, MSKA & Associates LLP, have issued an unmodified opinion on the financial statements, confirming the reliability of the reported figures. The dividend is subject to shareholder approval at the upcoming Annual General Meeting.
Key Highlights
Recommended a final dividend of ₹0.90 per equity share (90% of face value) for FY 2025-26.
Board approved audited standalone and consolidated financial results for the year ended March 31, 2026.
Statutory Auditors issued an audit report with an unmodified opinion for the financial year.
Dividend to be credited or dispatched within 30 days from the date of the Annual General Meeting.
👀 What to Watch
Investors should review the full financial statement for growth in key therapeutic segments and margin trends. The dividend recommendation is a positive signal of healthy cash flow and management's commitment to shareholder returns.
Marksans Pharma Receives USFDA Approval for Benzonatate Capsules (100 mg & 200 mg)
Marksans Pharma has received final USFDA approval for its Abbreviated New Drug Application (ANDA) for Benzonatate Capsules USP in 100 mg and 200 mg strengths. This product is a generic version of Pfizer's Tessalon Capsules and is used as a non-narcotic treatment for persistent cough and lung infections. The approval strengthens Marksans' upper respiratory portfolio in the US market, which is a key geography for the company. This development is expected to contribute to the company's export revenue growth and market share in the generic segment.
Key Highlights
Final USFDA approval for Benzonatate Capsules USP in 100 mg and 200 mg dosages.
Product is bioequivalent and therapeutically equivalent to Pfizer's Tessalon Capsules.
Targets the upper respiratory segment for treating persistent cough and bronchitis.
Expands the company's US portfolio which already includes CVS, CNS, and Pain Management.
👀 What to Watch
Investors should view this as a positive milestone for the company's US growth strategy. Monitor the management's guidance on the commercial launch timeline and potential market share capture.
